Towards eradication of malaria: is the WHO's RTS, S/AS01 vaccination effective enough?
N Arora, LC Anbalagan, AK Pannu - Risk Management and …, 2021 - Taylor & Francis
Background Recent advances in mosquito eradication and antimalarial treatments have
reduced the malaria burden only modestly. An effective malaria vaccine remains a high …
reduced the malaria burden only modestly. An effective malaria vaccine remains a high …
Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age
Background Plasmodium falciparum malaria is a pressing global health problem. A previous
study of the malaria vaccine RTS, S (which targets the circumsporozoite protein), given with …
study of the malaria vaccine RTS, S (which targets the circumsporozoite protein), given with …
Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial
Background Development of an effective malaria vaccine could greatly contribute to disease
control. RTS, S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium …
control. RTS, S/AS02A is a pre-erythrocytic vaccine candidate based on Plasmodium …
Malaria vaccines: the 60-year journey of hope and final success—lessons learned and future prospects
AA El-Moamly, MA El-Sweify - Tropical Medicine and Health, 2023 - Springer
Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …
of the world population is still exposed to the risk of contracting malaria. Developing an …
Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial
P Aide, JJ Aponte, M Renom, T Nhampossa… - PLoS …, 2010 - journals.plos.org
Background The RTS, S/AS02D vaccine has been shown to have a promising safety profile,
to be immunogenic and to confer protection against malaria in children and infants. Methods …
to be immunogenic and to confer protection against malaria in children and infants. Methods …
RTS, S/AS01 vaccine (Mosquirix™): an overview
MB Laurens - Human vaccines & immunotherapeutics, 2020 - Taylor & Francis
Malaria is an illness caused by Plasmodium parasites transmitted to humans by infected
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …
The development of the RTS, S malaria vaccine candidate: challenges and lessons
WR Ballou - Parasite immunology, 2009 - Wiley Online Library
RTS, S is the world's most advanced malaria vaccine candidate and is intended to protect
infants and young children living in malaria endemic areas of sub‐Saharan Africa against …
infants and young children living in malaria endemic areas of sub‐Saharan Africa against …
Duration of protection with RTS, S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of …
Summary Background RTS, S/AS02A is a pre-erythrocytic stage malaria vaccine that
provides partial protection against infection in malaria-naive adult volunteers and …
provides partial protection against infection in malaria-naive adult volunteers and …
The RTS, S vaccine—a chance to regain the upper hand against malaria?
Malaria is estimated by the World Health Organization (WHO) to have killed 627,000
individuals worldwide in 2020, with nearly 80% of deaths in African children younger than …
individuals worldwide in 2020, with nearly 80% of deaths in African children younger than …
Efficacy and safety of the RTS, S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 …
RTS, S Clinical Trials Partnership (2014) - PLoS medicine, 2014 - journals.plos.org
Background A malaria vaccine could be an important addition to current control strategies.
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …
We report the safety and vaccine efficacy (VE) of the RTS, S/AS01 vaccine during 18 mo …